Intravenous Immunoglobulin + Placebos + Normal Saline
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Epilepsy
Conditions
Autoimmune Epilepsy
Trial Timeline
Feb 1, 2016 → Dec 3, 2018
NCT ID
NCT02697292About Intravenous Immunoglobulin + Placebos + Normal Saline
Intravenous Immunoglobulin + Placebos + Normal Saline is a phase 3 stage product being developed by Grifols for Autoimmune Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02697292. Target conditions include Autoimmune Epilepsy.
What happened to similar drugs?
0 of 12 similar drugs in Autoimmune Epilepsy were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02697292 | Phase 3 | Terminated |
Competing Products
20 competing products in Autoimmune Epilepsy